Dilip Shanghvi

Dilip Shanghvi is the Chairman and Managing Director of Sun Pharmaceutical Industries Limited and founded that Company in 1982.

Sun Pharmaceuticals Industries Ltd. was listed on the main stock exchanges in India in 1994, and in 1997 the company began the first of its international acquisitions with an initial investment of US$7.5 million in Caraco Pharm Labs, Detroit. By 2000, Sun Pharma had already completed eight new acquisitions, added a research centre, tracked new therapies and penetrated international markets. Presently, all the products that Caraco markets are based on technology developed and transferred by Sun Pharma, which is possibly the first instance of an Indian company apportioning technology to a US company.

In May 2007, Sun Pharma had proposed to acquire Taro Pharmaceutical Industries Limited, which was be a major business-booster and was accomplished by mid-2008.

He has extensive experience in the pharmaceutical industry. Shanghvi is actively involved in international pharmaceutical markets and research and development functions at SPARC Ltd. Under the leadership of Shanghvi, Sun Pharmaceutical Industries Ltd. has recorded an all-round growth in the business.

He has an estimated wealth of $4.44 billion. Sun Pharmaceuticals is currently the fifth-largest drug maker in India. Shanghvi is estimated to be worth $6.1 billion as of 2011 by Forbes, and was ranked as the 13th richest person in India.